|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PVRL2 |
Gene summary for PVRL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PVRL2 | Gene ID | 5819 |
| Gene name | nectin cell adhesion molecule 2 | |
| Gene Alias | CD112 | |
| Cytomap | 19q13.32 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q92692 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5819 | PVRL2 | P1T-E | Human | Esophagus | ESCC | 1.67e-28 | 1.30e+00 | 0.0875 |
| 5819 | PVRL2 | P2T-E | Human | Esophagus | ESCC | 1.14e-66 | 1.18e+00 | 0.1177 |
| 5819 | PVRL2 | P4T-E | Human | Esophagus | ESCC | 1.07e-48 | 1.05e+00 | 0.1323 |
| 5819 | PVRL2 | P5T-E | Human | Esophagus | ESCC | 6.31e-48 | 8.39e-01 | 0.1327 |
| 5819 | PVRL2 | P8T-E | Human | Esophagus | ESCC | 9.07e-107 | 2.17e+00 | 0.0889 |
| 5819 | PVRL2 | P9T-E | Human | Esophagus | ESCC | 6.37e-40 | 9.23e-01 | 0.1131 |
| 5819 | PVRL2 | P10T-E | Human | Esophagus | ESCC | 8.28e-115 | 2.10e+00 | 0.116 |
| 5819 | PVRL2 | P11T-E | Human | Esophagus | ESCC | 4.31e-36 | 1.25e+00 | 0.1426 |
| 5819 | PVRL2 | P12T-E | Human | Esophagus | ESCC | 1.01e-76 | 1.36e+00 | 0.1122 |
| 5819 | PVRL2 | P15T-E | Human | Esophagus | ESCC | 1.27e-59 | 1.21e+00 | 0.1149 |
| 5819 | PVRL2 | P16T-E | Human | Esophagus | ESCC | 2.41e-29 | 5.09e-01 | 0.1153 |
| 5819 | PVRL2 | P17T-E | Human | Esophagus | ESCC | 4.98e-33 | 1.04e+00 | 0.1278 |
| 5819 | PVRL2 | P19T-E | Human | Esophagus | ESCC | 5.23e-14 | 8.13e-01 | 0.1662 |
| 5819 | PVRL2 | P20T-E | Human | Esophagus | ESCC | 7.21e-33 | 7.69e-01 | 0.1124 |
| 5819 | PVRL2 | P21T-E | Human | Esophagus | ESCC | 5.57e-40 | 7.76e-01 | 0.1617 |
| 5819 | PVRL2 | P22T-E | Human | Esophagus | ESCC | 2.86e-20 | 4.07e-01 | 0.1236 |
| 5819 | PVRL2 | P23T-E | Human | Esophagus | ESCC | 2.01e-82 | 1.91e+00 | 0.108 |
| 5819 | PVRL2 | P24T-E | Human | Esophagus | ESCC | 6.36e-70 | 1.09e+00 | 0.1287 |
| 5819 | PVRL2 | P26T-E | Human | Esophagus | ESCC | 2.45e-83 | 1.45e+00 | 0.1276 |
| 5819 | PVRL2 | P27T-E | Human | Esophagus | ESCC | 2.62e-77 | 1.36e+00 | 0.1055 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0452018 | Breast | Precancer | Adherens junction | 17/684 | 93/8465 | 1.11e-03 | 7.57e-03 | 5.80e-03 | 17 |
| hsa0452019 | Breast | Precancer | Adherens junction | 17/684 | 93/8465 | 1.11e-03 | 7.57e-03 | 5.80e-03 | 17 |
| hsa0452024 | Breast | DCIS | Adherens junction | 17/846 | 93/8465 | 9.95e-03 | 4.40e-02 | 3.24e-02 | 17 |
| hsa0452034 | Breast | DCIS | Adherens junction | 17/846 | 93/8465 | 9.95e-03 | 4.40e-02 | 3.24e-02 | 17 |
| hsa045202 | Colorectum | SER | Adherens junction | 37/1580 | 93/8465 | 1.54e-06 | 2.35e-05 | 1.71e-05 | 37 |
| hsa045203 | Colorectum | SER | Adherens junction | 37/1580 | 93/8465 | 1.54e-06 | 2.35e-05 | 1.71e-05 | 37 |
| hsa045208 | Colorectum | FAP | Adherens junction | 45/1404 | 93/8465 | 8.66e-13 | 2.89e-10 | 1.76e-10 | 45 |
| hsa045209 | Colorectum | FAP | Adherens junction | 45/1404 | 93/8465 | 8.66e-13 | 2.89e-10 | 1.76e-10 | 45 |
| hsa0452025 | Endometrium | AEH | Adherens junction | 36/1197 | 93/8465 | 3.49e-09 | 5.98e-08 | 4.37e-08 | 36 |
| hsa04520111 | Endometrium | AEH | Adherens junction | 36/1197 | 93/8465 | 3.49e-09 | 5.98e-08 | 4.37e-08 | 36 |
| hsa0452026 | Endometrium | EEC | Adherens junction | 36/1237 | 93/8465 | 8.57e-09 | 1.48e-07 | 1.11e-07 | 36 |
| hsa0452035 | Endometrium | EEC | Adherens junction | 36/1237 | 93/8465 | 8.57e-09 | 1.48e-07 | 1.11e-07 | 36 |
| hsa0452030 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
| hsa04520114 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
| hsa0452014 | Liver | NAFLD | Adherens junction | 37/1043 | 93/8465 | 1.50e-11 | 1.64e-09 | 1.32e-09 | 37 |
| hsa0452015 | Liver | NAFLD | Adherens junction | 37/1043 | 93/8465 | 1.50e-11 | 1.64e-09 | 1.32e-09 | 37 |
| hsa0452022 | Liver | Cirrhotic | Adherens junction | 52/2530 | 93/8465 | 1.36e-07 | 1.97e-06 | 1.21e-06 | 52 |
| hsa0452032 | Liver | Cirrhotic | Adherens junction | 52/2530 | 93/8465 | 1.36e-07 | 1.97e-06 | 1.21e-06 | 52 |
| hsa0452042 | Liver | HCC | Adherens junction | 68/4020 | 93/8465 | 3.99e-07 | 4.46e-06 | 2.48e-06 | 68 |
| hsa0452052 | Liver | HCC | Adherens junction | 68/4020 | 93/8465 | 3.99e-07 | 4.46e-06 | 2.48e-06 | 68 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |